

01-03-00

A

FISH & RICHARDSON P.C., P.A.

Frederick P. Fish
1855-1930

W.K. Richardson
1859-1951

December 29, 1999

3300 Dain Rauscher Plaza
60 South Sixth Street
Minneapolis, Minnesota
55402

Telephone
612 335-5070

Faxsimile
612 288-9696

Web Site
www.fr.com

Attorney Docket No.: 35284-03200 (10599-004001)

JC690 U.S.P.T.O.
09/474677
12/29/99

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Presented for filing is a new patent application claiming priority from a provisional patent application of:

BOSTON

DELAWARE

NEW YORK

SILICON VALLEY

SOUTHERN CALIFORNIA

TWIN CITIES

WASHINGTON, DC

Applicant: YASH SHARMA

Title: TREATMENT AND PREVENTION OF HIV AND OTHER VIRAL INFECTIONS

Enclosed are the following papers, including those required to receive a filing date under 37 CFR 1.53(b):

	<u>Pages</u>
Specification	28
Claims	2
Abstract	1
Declaration	2
Drawing(s)	3

Enclosures:

- Postcard
- Verified Statement Claiming Small Entity Status-Independent Inventor.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL235810698US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

December 29, 1999

Date of Deposit


Signature

Kenneth P. Lundblad

Typed or Printed Name of Person Signing Certificate

FISH & RICHARDSON P.C., P.A.

Assistant Commissioner for Patents
December 29, 1999
Page 2

Under 35 USC §120, this application claims the benefit of prior U.S. application 09/015,830, filed January 29, 1998.

Under 35 USC §119(e)(1), this application claims the benefit of prior U.S. provisional application 60/114,540, filed December 29, 1998.

Basic filing fee	\$345
Total claims in excess of 20 times \$9	\$99
Independent claims in excess of 3 times \$39	\$78
Fee for multiple dependent claims	\$0
Total filing fee:	\$522

A check for the filing fee is enclosed. Please apply any other required fees or any credits to deposit account 06-1050, referencing the attorney docket number shown above.

If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at (612) 335-5070.

Kindly acknowledge receipt of this application by returning the enclosed postcard.

Please send all correspondence to:

W. JACKSON MATNEY, JR.
Milbank, Tweed, Hadley & McCloy LLP
International Square Building
1825 Eye Street, N.W.
Washington, D.C. 20006

Respectfully submitted,



Monica McCormick Graham, Ph.D.
Reg. No. 42,600
Enclosures
MMG/par
60004690.doc

12/29/99 14:13 FAX 302 835 78867

MTHM DC

1004

VERIFIED STATEMENT (DECLARATION)
CLAIMING SMALL ENTITY STATUS (37 C.F.R. §§ 1.9(f) & 1.27(b))
INDEPENDENT INVENTOR

Serial No.	Filing Date	Patent No.	Issue Date
<u>Applicant/Patentee: YASH SHARMA</u>			
<u>Invention: TREATMENT AND PREVENTION OF HIV AND OTHER VIRAL INFECTIONS</u>			

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 C.F.R. § 1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office in:

- the specification to be filed herewith.
 the application identified above.
 the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 C.F.R. § 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, and patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF INVENTOR: Yash Sharma

SIGNATURE OF INVENTOR: Yash SharmaDATE: Dec 29 1999

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: TREATMENT AND PREVENTION OF HIV AND OTHER
VIRAL INFECTIONS

APPLICANT: YASH SHARMA


CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL235810698US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

December 29, 1999

Date of Deposit


Signature

Kenneth P. Lundblad

Typed or Printed Name of Person Signing Certificate

jc690 U.S. PTO
12/29/99

TREATMENT AND PREVENTION OF HIV AND OTHER VIRAL INFECTIONS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Serial No. 09/015,830, filed January 29, 1998 and claims priority from U.S. Provisional Application Serial No. 60/114,540, filed December 29, 1998.

5

BACKGROUND OF THE INVENTION

Promising treatments for human immunodeficiency virus-type (HIV) have been developed over the past few years, including combination therapy with protease inhibitors. The cost associated with such treatments is prohibitive, however, as the spread of Acquired Immune Deficiency Syndrome (AIDS) is concentrated in regions of the world with limited financial resources. Although the AIDS incidence and mortality have been decreasing in the United States, it is estimated that 16,000 people worldwide are being infected with HIV each day. In certain African countries, infection rates have reached 25%. See, Balter, M., Science, 1998, 280:1863-1864. Treatment success also has been limited by poor tolerance of the treatments by patients and the emergence of resistant strains of HIV. Thus, a need exists for an effective HIV treatment that is well tolerated and relatively inexpensive.

SUMMARY OF THE INVENTION

The invention is based on the discovery that N-glycolylneuraminic acid and related compounds can be used to prevent or treat viral infections, as well as other pathogenic infections. N-glycolylneuraminic acid is a complex galactose molecule that is produced in many non-human mammals. N-glycolylneuraminic acid was identified from extracts of baboon peripheral blood monocytes (PBMCs) that were capable of inhibiting HIV-1 replication in and/or infection of human cells. As N-glycolylneuraminic acid is a carbohydrate, toxicity is minimal. Thus, the invention provides a safe and effective treatment of HIV.

20
25

In one aspect, the invention features a method for preventing or treating a viral infection in a subject. The method includes administering N-glycolylneuraminic acid or a derivative thereof, e.g., phosphorylated N-glycolylneuraminic acid or sulfated N-glycolylneuraminic acid, to the subject in an amount effective to prevent or treat the viral infection. N-glycolylneuraminic acid can be synthetic or extracted from a biological sample. The viral infection can be from an enveloped retrovirus such as HIV, hepatitis C virus, or a herpes virus. N-glycolylneuraminic acid or the derivative thereof can be administered intravenously, subcutaneously, orally, by inhalation, or transdermally. The method further can include monitoring the subject for the presence of the viral infection.

The amount of N-glycolylneuraminic acid or the derivative thereof can be about 1 mg to about 1000 mg per administration, about 10 mg to about 100 mg per administration, or about 30 mg to about 80 mg per administration. N-glycolylneuraminic acid or the derivative thereof can be administered daily.

In another aspect, the invention features a method for treating an immune mediated disease, e.g., cancer, in a patient. The method includes administering N-glycolylneuraminic acid or a derivative thereof to the patient in an amount effective to treat the immune mediated disease in the patient.

The invention also features a method for preventing or treating a pathogenic infection in a patient. The method includes administering N-glycolylneuraminic acid or a derivative thereof to the patient in an amount effective to prevent or treat the pathogenic infection. The pathogenic infection can be, for example, a bacterial or parasitic infection. The pathogen can be, for example, influenza or malaria.

A method for treating a blood product intended for transfusion into a subject also is featured. The method includes adding N-glycolylneuraminic acid or a derivative thereof to the blood product in an amount effective to reduce or eliminate the risk of infection of the subject with a pathogen associated with transfusion of the blood product.

In yet another aspect, the invention features a method for treating a viral infection in a subject that includes administering a first anti-viral agent and a second anti-viral agent to the subject in amounts effective to treat the viral infection, wherein the first anti-viral agent is N-glycolylneuraminic acid or a derivative thereof. The second anti-viral agent can be, for

example a reverse transcriptase inhibitor or a protease inhibitor. The first and second anti-viral agents can be conjugated to each other.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph that illustrates reverse transcriptase assay for HIV infected CEM-TART cells treated with N-glycolylneuraminic acid.

Figure 2 is a chromatogram that depicts the HPLC Profile of LUKOR (C18 column; 0.1% TFA/water and a 0-100% ACN gradient; UV detection A280).

Figures 3A-3C are graphs that illustrate the reverse transcriptase activity in infected cells treated with LUKOR, N-glycolylneuraminic acid, and N-acetylneuraminic acid, respectively.

DETAILED DESCRIPTION

The invention provides methods for treating or preventing viral infections in a subject that include administering N-glycolylneuraminic acid or a derivative thereof to the subject. N-glycolylneuraminic acid ($C_{11}H_{19}NO_{10}$, MW 325.3) is the hydroxylated derivative of N-acetylneuraminic acid (sialic acid), which is the most prevalent sialic acid in humans. N-glycolylneuraminic acid typically is not detectable in humans. CMP-N-acetylneuraminic acid hydroxylase, the enzyme that converts N-acetylneuraminic acid to N-glycolylneuraminic acid, is not detectable in humans as the gene encoding this enzyme is inactivated by a 92 base

pair deletion that results in a frameshift mutation. See, Irie and Suzuki, Biochem. Biophys. Res. Commun., 1998, 248(2):330-333; and Chou et al., Proc. Natl. Acad. Sci. USA, 1998, 95(20):11751-11756. Without being limited to a particular mechanism, the presence of N-glycolylneuraminic acid on the cell surface in non-human primates may provide immunity to
5 HIV infection in such species.

N-glycolylneuraminic acid or derivatives thereof also can be used to treat blood products that are to be transfused into a patient. For example, N-glycolylneuraminic acid or a derivative thereof can be added to donor blood bags to reduce or eliminate the risk of infection in a subject with a pathogen associated with transfusion of the blood. As described herein, N-glycolylneuraminic acid does not alter clotting activity, blood stability, or blood
10 cell parameters.

Preparation of N-glycolylneuraminic acid or derivatives thereof

As used herein, "derivative" refers to a compound that is similar in structure to N-glycolylneuraminic acid, such as the compounds described in U.S. Patent Nos. 4,774,326 and 4,774,327. Additional non-limiting examples of derivatives include phosphorylated or sulfated N-glycolylneuraminic acid, N-glycolylneuraminic acid salts, O-glycolylneuraminic acid, as well as other substituted N-glycolylneuraminic acid compounds.
15

N-glycolylneuraminic acid can be purchased commercially from, for example, Sigma Chemical Company, St. Louis, MO. N-glycolylneuraminic acid also can be synthesized. For example, CMP-N-acetylneuraminic acid hydroxylase can be used to synthesize N-glycolylneuraminic acid as its CMP-glycoside. See, Schlenzka et al., Glycobiology, 1994, 4(5):675-683. Non-enzymatic methods of synthesis include, for example, synthesis from N-acetylneuraminic acid using methanol or hydrochloric acid and benzylalcohol. Other synthesis methods are described in Choi et al., J. Org. Chem., 1996,
20 61:8/39 (from mannosamine), Faillard et al., J. Physiol. Chem., 1965, 344:167 (from glucosamine), U.S. Patent No. 4,774,326, and U.S. Patent No. 4,774,327.

Alternatively, N-glycolylneuraminic acid can be purified from biological samples from non-human mammals (e.g., pigs or baboons). In particular, N-glycolylneuraminic acid can be purified from pig submaxillary glands or baboon PBMCs. Generally, PBMCs are isolated from whole blood using, for example, Ficol-Hypaque density-gradient
30 centrifugation. Cells are lysed in a hypotonic solution, e.g., sterile, distilled water. Proteins and nucleic acids are removed from the lysed cells by precipitation, for example, with a

stabilizing solution containing 10% v/v calcium chloride and potassium chloride in phosphate-buffered saline, pH 7.4. After removal of the precipitate by centrifugation, the supernatant can be clarified by filtration through a 0.22 μ m filter and sterilized. This purification procedure removes substantially all macromolecule components from the extract, 5 leaving N-glycolylneuraminic acid and other small molecular weight components. Extracts at this stage of purification have potent antiviral activity.

Further purification procedures such as high-pressure liquid chromatography (HPLC) can be used isolate N-glycolylneuraminic acid from the extract. For example, HPLC can be performed using a C18 column with a mobile phase of 0.1% tetrafluoroacetic acid 10 (TFA) in water and a gradient of 0-100% acetonitrile (ACN).

Methods of Treatment

Methods of the invention include administering N-glycolylneuraminic acid or a derivative thereof to a subject in an amount effective to prevent or treat the viral infection. N-glycolylneuraminic acid or a derivative thereof can be administered to either subjects at risk for a viral infection or subjects that have been infected. Subjects that are at risk for infection include, for example, health care workers that may have been exposed to a virus through a needle stick or other patient contact, or patients involved in high-risk activities such as intravenous drug use. N-glycolylneuraminic acid or derivatives thereof are particularly useful for treatment or prevention of enveloped retrovirus infections, e.g., HIV, hepatitis C virus (HCV), or herpes virus.

The concentration of N-glycolylneuraminic acid or a derivative thereof effective for preventing or treating a viral infection in a subject may vary, depending on a number of factors, including the preferred dosage of the compound to be administered, the chemical 25 characteristics of the compounds employed, the formulation of the compound excipients and the route of administration. The optimal dosage of N-glycolylneuraminic acid to be administered also may depend on such variables as the overall health status of the particular patient and the relative biological efficacy of the compound selected.

Typically, about 1 mg to about 1000 mg of N-glycolylneuraminic acid or a derivative 30 thereof is administered to the subject. For example, about 10 mg to about 100 mg or about 30 mg to about 80 mg of N-glycolylneuraminic acid or a derivative thereof can be administered. N-glycolylneuraminic acid or a derivative thereof can be administered as a

single, daily dose or administered multiple times over the course of a day. In addition, delayed release formulations can be used such that administrations of N-glycolylneuraminic acid or a derivative thereof are less frequent. N-glycolylneuraminic acid or a derivative thereof can be administered by any route of administration including, for example, orally, intravenously, subcutaneously, transdermally, or by inhalation.

One advantage of using carbohydrate-based therapy is that carbohydrates do not naturally kill the pathogens, but simply prevent them from binding to a cell. Therefore, the presently described therapy should not engender the type of resistance that pathogens typically develop against therapeutics. This profound advantage allows carbohydrate treatment to be used not only in the treatment, but also in the prevention of infection.

The method of the invention further can include monitoring the subject for the presence of the viral infection. Viral load of the subject (i.e., amount of virus/ ml of blood) can be determined using polymerase chain reaction (PCR) assays (e.g., Roche Amplicor HIV-1 or HCV Monitor) or branched DNA assays (e.g., Chiron Quantiplex) to detect copies of viral RNA. P24 antigen (for HIV) or other viral antigens also can be assessed as a measure of viral load. Monitoring of treatment also can include determining the subject's number of CD4 cells, CD4 percentage, number of CD8 cells, CD8 percentage, or ratio of CD4 cells/CD8 cells.

In some embodiments, the method further includes administering N-glycolylneuraminic acid in combination with other compounds such as polypeptides or therapeutic agents. Non-limiting examples of therapeutic agents include antibiotics, chemotherapy agents, and other antiviral agents such as reverse transcriptase inhibitors (e.g., AZT, ddI, ddC, d4T, and 3TC) or protease inhibitors (e.g., NEVIROAPINE, SAQUINAVIR, RITNOVIR, and INDINARVIR). N-glycolylneuraminic acid also can be conjugated to other compounds or therapeutic agents using standard methodologies and administered to a subject.

Pharmaceutical Compositions

N-glycolylneuraminic acid or a derivative thereof may be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable excipients or carriers. Such compounds and compositions may be prepared for parenteral administration,

particularly in the form of liquid solutions or suspensions in aqueous physiological buffer solutions; for oral administration, particularly in the form of tablets or capsules; or for intranasal administration, particularly in the form of powders, nasal drops, or aerosols. Compositions for other routes of administration may be prepared as desired using standard methods.

Formulations for parenteral administration may contain as common excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxethylene-polyoxypropylene copolymers are examples of excipients for controlling the release of a compound of the invention *in vivo*.

Other suitable parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration may contain excipients such as lactose, if desired. Inhalation formulations may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate, and deoxycholate, or they may be oily solutions for administration in the form of nasal drops. If desired, the compounds can be formulated as gels to be applied intranasally. Formulations for parenteral administration also may include glycocholate for buccal administration.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1 – Isolation of a Small Molecule from Baboon Blood: Peripheral blood monocytes (PBMC) were isolated from whole baboon blood using Ficoll-Hypaque density gradient centrifugation or from PBMCs further expanded in tissue culture following activation with phytohemagglutinin –P (PHA-P) and growth in medium containing interleukin-2 (IL-2). In either case, the PBMCs first were washed 3 times with sterile phosphate-buffered saline (PBS) and pelleted by centrifugation. The cell pellet then was lysed by resuspension in sterile H₂O and held for 96 hours at 4°C. Proteins and nucleic acids were precipitated from the extract and the remaining components in the extract were stabilized using 10% (v/v) calcium phosphate buffer (pH 7.4) containing 0.01 % calcium chloride and 0.001% ascorbic acid. The solution was clarified by centrifugation followed by

filtration through a 0.22 μ m filter. This final filtrate represented a 1:50 dilution of the initial cell lysate and is hereafter referred to as LUKOR. In some instances, the LUKOR preparation was sterilized by Cobalt radiation at 2.5 mRADs for 3 hours (Neutron Products, Inc. Gaithersburg, MD).

The biological activity of LUKOR was evaluated by determining if p24 expression from HIV-infected human mononuclear cells was inhibited. Human PBMCs were obtained from the American Red Cross and incubated with ~100 TCID₅₀ (tissue culture infective dose) of HIV-1 (Strain IIIB) at 37°C for 3 hours. Excess free virus was removed at the end of the incubation period by washing the cells two times with PBS. Uninfected control PBMCs were cultured in RPMI (Difco) plus 10% bovine calf serum, 100 U/ml penicillin, and 100 μ g/ml streptomycin, at 37°C and 5% CO₂. A standard preparation of LUKOR was serially diluted 1:2, 1:4, 1:8, 1:16, 1:32, and 1:64 in saline, and 750 μ l of each dilution were added to each well containing 750 μ L medium and 2 x 10⁵ infected cells. Positive controls (HIV-infected PBMCs with 750 μ L of medium in the absence of LUKOR), and negative controls (non-infected PBMCs in the presence of LUKOR) were included in each experiment. An HIV-1 p24 Antigen Kit (Dupont, Wilmington, DE) was used to determine the p24 output in all cell samples after 5 days in culture by measuring optical density of the cultures at 490 nm. Typical results with LUKOR isolated directly from whole blood PBMCs or from PBMCs expanded in tissue culture are shown in Table 1.

TABLE 1
p24 Expression in Infected Human PBMCs in the Presence or Absence of LUKOR

Sample	LUKOR Dilution (v/v)	p24 Expression (pg HIV p24/ml)
Negative Control (uninfected cells)	+ LUKOR	97
Positive Control (infected cells)	- LUKOR	10,850,000
WB*-LUKOR	1:2	320
WB- LUKOR	1:8	871
WB- LUKOR	1:16	824
WB- LUKOR	1:64	865
TC**-LUKOR	1:100	480
TC-LUKOR	1:200	660
TC-LUKOR	1:400	380
TC-LUKOR	1:800	620

*LUKOR prepared from PBMCs of whole baboon blood (WB-Lukor)

**LUKOR prepared from PBMCs expanded in tissue culture (TC-Lukor)

The data in Table 1 indicate that at all dilutions used (up to 1:64 for the whole baboon blood and 1:800 dilution for tissue culture LUKOR), LUKOR was effective in reducing expression of p24. This suggests that LUKOR can inhibit HIV replication. Furthermore, LUKOR was active both from baboon PBMCs isolated from fresh blood, as well as from baboon PBMCs maintained in tissue culture for 4 weeks. Similar results also were seen with lysates stored for 6 weeks at 4°C, suggesting that the active component or components were fairly stable to refrigerated storage conditions. Activity of the extracts also was maintained after acid treatment or boiling of the extract (Table 2), as measured by reverse transcriptase activity. Results in Table 2 are presented as "% inhibition". Similar extracts made from rabbit and human PBMCs did not significantly inhibit production of p24 at dilutions ranging from 1:4 to 1:250 (see Table 2).

TABLE 2
Comparison of Extracts from Baboon, Humans, and Rabbits

Lysate	Day	Dilution				Control
		1:4	1:20	1:100	1:250	
Baboon PBMC	5	8.6	63.6	49.2	45.7	115
PHA-Baboon PBMC	5	17	26	48	41	
Human PBMC	5	4.7	3.4	5.7	4.7	
Rabbit PBMC	5	1.3	2.5	1.7	1.2	
Buffer-no cells	5	1.4	1.3	1.8	1.8	
Baboon PBMC (boiled)	5	9	29	72	41	
Baboon PMBC (acid treated)	5	3	31	42	99	

The transmission of HIV-1 from infected T-cells to uninfected T-cells during co-cultivation in the presence of LUKOR also was evaluated by p24 production. Supernatants from SUPT-1 T-cells infected with HIV-1 strains GT63 or GT65 were added to uninfected SUPT-1 cells, which were isolated from human blood. After 48 hours, the cells were treated with LUKOR for 1 hour, washed with fresh medium, and cultured for 5 days at which time virus replication was measured by assaying HIV-1 p24 in the supernatants. The infectivities of both strains of HIV-1 (GT63 and GT65) were significantly depressed by treatment of the infected cells for one hour with either a 1:10 or 1:5 dilution with LUKOR (Table 3).

TABLE 3
Inhibition of Cellular Infectivity by LUKOR

Treatment	HIV-1 (GT63)*	HIV-1 (GT65)*
1:5 (v/v) LUKOR	25,600	837
1:10 (v/v) LUKOR	353,000	1,770
No LUKOR	9,680,000	4,478,000

*Results are expressed in picograms of HIV-1 p24/ml

15

20

Reverse transcriptase activity was measured after detergent treatment of cell supernatants, by determining [³H]-TTP incorporation into poly(rA):oligo(dT)(rAdT) or by

[³H]-GTP incorporation into poly(rC):oligo(dG)((rCdG) homopolymer template/primer systems. See, Walker et al., J. Virol., 1991, 65(11):5921-5927. The reverse transcriptase inhibitors AZTTP (3'-Azido-2',3'-dideoxythymidine-5'-triphosphate) and UC38 (NSC 629243, non-nucleoside reverse transcriptase inhibitor) served as positive controls. Rice, W. G., et.al. 1993, Proc Natl Acad Sci USA 90:9721-9724. Cells (CEM-TART, NIH AIDS reagent program, catalog #136) were treated overnight with various amounts of LUKOR prior to incubation for 6 days with a clone of HIV-1. A dilution of 1:500 (LUKOR from PBMCs in cell culture) consistently resulted in 60-70% inhibition of HIV RT activity (Figure 1). This compared favorably to 1.6nM concentrations of AZT. Dilutions of LUKOR greater than 1:500 (>1:1,000) did not exhibit significant RT inhibitory activity.

HIV-protease activity also was assayed in the presence or absence of various dilutions of LUKOR. The assay contained HIV-1 protease (1.25µg/ml), 0.5 M KHPO₄ buffer (pH 6.5), 5% glycerol, 3mM DTT, 0.5mM EDTA, and 0.75M ammonium sulfate, and was initiated by the addition of the sp211 substrate (Ala-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-amide) to attain a final concentration of 0.1044 mg/ml. The reaction proceeded at 37°C for 30 minutes and then was quenched with 80mM Guanidine-HCl in TFA. The amount of sp211 substrate remaining at the termination of the reaction was determined by reverse phase HPLC. The effect of LUKOR on the inhibition of HIV protease is shown in Table 4.

TABLE 4
Inhibition of HIV protease by LUKOR from Baboon PBMCs From Cell Culture

Dilution of LUKOR	Inhibition of HIV Protease (%)
Undiluted	33%
1:10	26%
1:100	42%
1:1000	13%
No LUKOR	0%

The specificity of the anti-viral activity of LUKOR was tested against various strains of HIV and SIV-1 (simian immunodeficiency virus). The target cells were human PBMCs that had been incubated with a specified virus overnight. Following incubation, the cells were washed and plated in the presence of various dilutions of LUKOR. One-half of

the medium in each well was changed at 3-4 day intervals. Antigen capture was determined with the HIV p24 OTC kit (Organon) at day 10. The control included HIV-infected PBMCs in the absence of LUKOR. Results of these experiments are presented in Table 5 as ng/ml p24, with % inhibition in parentheses. In spite of low levels of p24 expression in HIV-1 strains NS1 (non-syncytium inducing) and SI (syncytium inducing), dilutions of LUKOR caused significant inhibition of viral p24 expression in HIV-1 NS1 and SI, H9/IIIB, and SIV-1 (MAC 251).

TABLE 5
Inhibition of p24 Production in Infected PBMCs

Virus	Dilution			
	1:4	1:20	1:100	Control
HIV-1 (NSI)	5.3 (-60)	3.7 (-12)	0.96 (71)	3.3
	1.9 (-58)	1.4 (-16)	0.468 (61)	1.2
HIV-1 (SI)	3.9 (-2)	2.9 (40)	3.6 (6)	3.8
H9/IIIB	427 (4)	457 (-3)	385 (13)	442
SIV-1(MAC251)	6.5 (97)	85 (69)	54 (80)	271

A series of *in vitro* and *in vivo* toxicology studies were conducted to evaluate the potential adverse effects of LUKOR on human blood cells, blood clotting factors, and in rats administered intravenous LUKOR repeatedly over 28 days. Freshly drawn heparinized whole blood (1ml) was diluted 1:4 in PBS (pH 7.4) and 0.1 ml of LUKOR (freshly prepared) was added per ml of diluted whole blood. Two aliquots of the blood were maintained at 4°C for 21 and 42 days. Extract was not added to the control samples (freshly drawn blood, and blood stored for 21 and 42 days). Results are reported in Table 6. LUKOR had no effect on red blood cell (RBC) count, white blood cell (WBC) count, hemoglobin (Hb), hematocrit (Hct), mean corpuscular volume (MCV), mean cell hemoglobin (MCH), RBC osmotic fragility, and hemolysis. The control blood sample that was stored for 42 days began to deteriorate. Reference values were 5.4 million/mm³ RBCs, 12.7g/100ml for Hg content, and 33.3% for Hct (volume of cells in 100ml of blood).

TABLE 6
Addition of LUKOR to whole blood

Parameter	Day 0		Day 21		Day 42	
	Untreated	Treated	Untreated	Treated	Untreated	Treated
RBC	5.3	5.3	4.2	5.1	3.0	5.1
Hb	12.8	12.9	8.4	12.8	6.3	12.6
Hct	32.3%	32.3%	20.2%	33.0%	15.8%	32.0%
Lysis	0%	0%	10%	0%	40%	0%
45% saline	0%	0%	92%	0%	58.4%	0%

5 The effects of LUKOR on Factor VIII and Factor IX clotting activities were determined by adding LUKOR (1:10 dilution) to human plasma and incubating the samples for 1, 2, 5, and 23 hours at 37°C. The samples were frozen and assayed for Factor VIII and Factor IX clotting activity by a one-stage APTT method using 0.15 M sodium chloride as the control. Denson, *Br. J. Haematol.*, 1973, 24(4):451-461. Samples also were incubated at room temperature and at 4°C. Factor VIII and Factor IX activities of the samples treated with LUKOR (0.076 and 0.389 units/ml respectively) were not different from saline controls (Table 7, % activity remaining).

TABLE 7
Clotting Activity in Treated Samples

Time (Hrs)	FVIII/saline	FVIII/LUKOR	FIX/Saline	FIX/LUKOR
0	91.81	111.11	91.13	93.01
1	93.92	114.29	98.77	103.06
2	80.11	120.91	96.95	93.83
5	93.5	114.29	93.51	93.68
23	67.95	87.45	40.14	62.03

10 In vivo toxicology of LUKOR was examined using Sprague-Dawley CD albino rats. Five male rats and 5 female rats were administered 1 ml of LUKOR per day by intravenous injection into the tail vein on 6 occasions (on Days 1, 3, 5, 7, 9 and 28). All 15 animals were examined twice daily for mortality and signs of ill health or reaction to treatment, with a more detailed examination performed weekly. There were no treatment-related clinical signs and the animals did not develop hypersensitivity reactions by the end of the experiment on Day 28. No treatment-related effects on food consumption or weight gain were observed. Blood samples were collected under anesthesia from the orbital sinus, 24 hours following the dose at day 9, and again from the abdominal aorta at necropsy at day 28.

All animals were euthanized by exsanguinations from the abdominal aorta following anesthesia. At the termination of the study on Day 28, hematological evaluations were performed on all animals. There were no mortalities, no treatment-related clinical observations, or effects on white cell parameters. Mean values for female animals generally were lower than male animal, but the difference was insignificant considering the normal range. Therefore, it appears that LUKOR can be administered intravenously.

The above studies indicate that an aqueous soluble material can be extracted from baboon PBMCs. This material is active in reducing HIV-infection or replication *in vitro*. Without being limited to a particular mechanism, N-glycolylneuraminic acid may not directly inhibit HIV-1 protease or reverse transcriptase.

Example 2 - Cytotoxicity of LUKOR on Cultured Blood Mononuclear Cells:

Cultured human blood mononuclear cells were cultured in the presence of varying concentrations of LUKOR for 7 days. Solutions containing different concentrations of LUKOR were prepared by diluting the stock solution of LUKOR (1mg/mL) 1:4, 1:20, 1:100, and 1:500 with PBS. An equal volume of each dilution of LUKOR was added to cultured cells. Medium was changed at Day 3. The resulting cell counts at each concentration of LUKOR are listed in Table 8. A colorimetric assay was used to assess cytotoxicity. A WST-1 test kit (a tetrazolium compound that is the sodium salt of 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) was used in this assay (Roche Diagnostics, Indianapolis, IN). As indicated in Table 8, no cytotoxicity was observed and cell count was maintained at varying concentrations of LUKOR.

TABLE 8
Cytotoxicity of LUKOR

Dilution (1X)	WST-1 (%)	Cell Count (%)
0	100	100
4	84	78.8
20	98	106
100	101	100
500	104	106

Example 3 – Identification of Active Component from LUKOR: The soluble lysate isolated from PBMCs (LUKOR) was fractionated by HPLC as a first step in

the identification of the active component. A C18 column (Delta Pak, 15 μ m, 300 \AA , 0.39x30 cm) with a mobile phase of 0.1% tetrafluoroacetic acid (TFA) in water and a gradient of 0-100% acetonitrile (ACN) was used to separate the components in the cell lysate. One major peak eluting with 30% ACN and two minor peaks at 50% ACN were observed (Figure 2).

5 The 3 peaks, designated HPLC-1, HPLC-2, and HPLC-3, were collected separately and lyophilized and stored for further characterization by mass spectrometry and NMR.

10 Mass spectrometry was performed with a VG BioQ triple quadrupole mass spectrometer operating in the positive ion electrospray ionization mode using the following parameters: scan range m/z 100-950 and 35-700; cone voltage 57V to 63V; source temperature 80°C to 100°C. Calibration was performed with direction injection analysis of CsI prior to LC-MS. A distinct aromatic ring absorbance with a peak maximum at 258 nm was detected. Behavior of the compound was consistent with a small molecular weight compound. Sample related masses of 86, 194, and 288 were identified. The sample related masses of 86 and 194 represented less than 1% of total. It was determined that the sample mass of 288 was composed of carbon, hydrogen, oxygen, and a single nitrogen atom.

15 Proton NMR also was performed on the extract in a solution of D₂O using a modified Nicolet NT 360 MH3 spectrometer operating with a single 0.5 μ sec. excitation pulse and a one second re-cycle delay. Signals were detected with shifts between 3.1-3.7ppm.

20 The active component of LUKOR was identified as N-glycolylneuraminic acid based on the molecular weight and chemical composition. Data supporting this conclusion are described below.

25 **Example 4—Specificity of Inhibition:** Research grade purified d-Galactose (CAT# g404, lot 117H00431, FW 180.2, Sigma Chemical Co., St. Louis, MO) was dissolved in saline at a concentration of 5mg/ml. The solution was allowed to stand at room temperature for 15 minutes and mixed by vortex until the galactose was completely dissolved. The galactose solution was divided into two equal aliquots. Stabilizing solution (0.1 ml) was added to one aliquot, then vortexed and incubated at room temperature for 30 minutes. After 30 mixing again, the mixture was centrifuged at 1500g for 30 minutes and the supernatant was filtered through a 0.2 μ m filter and transferred to a sterile 15 ml tube. The solution was sterilized by gamma radiation (2.5 mega RADs) with 15 minutes exposure. The aliquot

without the stabilizing solution was labeled "1A" and the aliquot containing the stabilized solution was labeled "1B". Solutions of N-glycolylneuraminic acid (CAT# g2755, lot # 27H0485, FW325.3, Sigma Chemical Co., 5mg/ml) and galactose- α 1,3-galactose (α 1, 3 galactosebios, V-Labs, Inc., Covington, LA, 5mg/ml) were prepared as described for galactose, and were labeled "2A" and "2B" and "3A" and "3B", respectively. Solutions 1 and 2 (galactose and N-glycolylneuraminic acid, respectively) were mixed in equal volumes to prepare solution 4. Each of the test solutions were diluted 1:20 1:40, 1:80, and 1:160 in saline. Control solutions were water.

One ml of each of the dilutions of the test solution or control was mixed with an equal volume of HIV-1_{III B} (~50 TCID₅₀ /2x10⁵ cells) to infect activated human PBMCs overnight at 37°C (3x10⁵ cells/dilution). HIV-1_{III B} is a laboratory-adapted strain. The cells then were washed and placed in culture media containing the indicated dilution of the test solution in triplicate wells (1x10³ cells per well, ½ medium changes with media containing the indicated dilutions of test solution were made at ~3 day intervals). The conditioned media were tested for HIV-1 P24 output on day 9 using the DuPont P24 assay kit. The control was infected PBMCs in the absence of test solutions. Results are shown in Table 9 and are measured as the Inhibition% of the control. As seen in Table 9, solutions containing N-glycolylneuraminic acid inhibited P24 output, while galactose and N-acetylneuraminic acid did not.

TABLE 9
N-Glycolylneuraminic Acid Treatment Inhibits p24 Output

SAMPLE	DILUTION				
	1:10	1:20	1:40	1:80	1:160
1A	4	5	4	2	2
1B	7	5	3	4	2
2A	94	78	66	41	19
2B	93	81	61	37	16
3A	4.3	3.6	2.2	1.4	0.4
3B	4.6	3.6	1.8	1.1	0.5
4A	97	88	72	58	46
4B	94	82	65	56	45

The test was repeated using test solutions stored at 4°C. In this experiment, the dilutions were mixed with HIV-1 IIIB virus at the time of infecting the activated human PBMCs for 3 hours. The cells then were washed and incubated in triplicate wells (1×10^3 cells/well) in the presence of the indicated dilution of the test solution. One half media changes included the test solution dilutions. Conditioned media were tested for P24 output by the antigen capture assay on day 6. Results are shown in Table 10 and are presented as the inhibition % of control (no carbohydrate added).

TABLE 10
Inhibition % of Control

SAMPLE	Dilution				
	1:10	1:20	1:40	1:80	1:160
2A	96	78	62	47	17
2B	88	74	59	44	13

In addition, a similar experiment was performed, except that test solutions were added post infection, at the time of plating into the triplicate wells. Results are shown in Table 11.

TABLE 11
Inhibition % of Control

SAMPLE	Dilution				
	1:10	1:20	1:40	1:80	1:160
2A	95	75	66	30	16
2B	82	70	61	26	15
4A	88	71	53	32	14
4B	87	70	45	26	11

5

This experiment was repeated using further dilutions of the test solution containing N-glycolylneuraminic acid to determine the endpoint of the inhibition. Results are shown in Table 12. The lowest effective concentration for inhibition of HIV p24 output was 3ng/ml.

TABLE 12
Inhibition % of Control

SAMPLE	DILUTION		
	1:20	1:100	1:1000
2A	88	55	7
2B	78	42	1

Example 5--Efficacy of N-Glycolylneuraminic Acid Treatment in CEM-SS and

PBMC cells: N-glycolylneuraminic acid (approximately 90% purity; MW325.3) was purchased from Sigma Chemicals (St. Louis, MO) and dissolved in dH₂O to make an 80mM stock solution. The stock solution was diluted to a starting concentration of 200μM and nine one-half log serial dilutions thereafter. PBMCs were isolated from fresh human blood obtained commercially from the American Red Cross (Baltimore, Maryland). CEM-SS cells were obtained from the NIH AIDS reagent program. The low passage, lymphotropic clinical isolate ROJO was obtained from a pediatric patient attending the AIDS Clinic at the University of Alabama at Birmingham. Phytohemagglutinin (PHA-P) was obtained from Sigma Chemical Co. (St. Louis, MO) and recombinant IL-2 was obtained from Amgen (San Francisco, CA). As a positive control for antiviral assays, AZT was obtained from the NIH AIDS Reagent Program. HIV-1_{RF} also was obtained from the NIH AIDS reagent program.

Tritiated thymidine triphosphate was obtained from New England Nuclear (Boston, MA). Each plate in each experiment contained cell control wells (cells only), virus control wells (cells plus virus), drug toxicity control wells (cells plus drug only), drug colorimetric control wells (drug only) as well as experimental wells (drug plus cells plus virus).

5 Cell Preparation: Prior to infection, CEM-SS cells were grown in complete tissue culture medium (RPMI 1640 medium with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 10 µg/mL gentamycin) and transferred to T-150 flasks. On the day preceding the assay, the cells were split 1:2 to assure the cells would be in an exponential growth phase at time of infection. On the day of assay, 10 the cells were washed twice with tissue culture medium and resuspended in fresh tissue culture medium. Total cell and viability counting were performed using a hemacytometer and trypan blue dye exclusion. Cell viability was greater than 95% for the cells to be utilized in the assay. The cells were pelleted and resuspended at 2.5×10^4 cells per mL in tissue culture medium. Cells were added to the drug-containing plates in a volume of 50 µL.

15 Fresh human PBMCs were isolated from voluntary Red Cross donors, seronegative for HIV and HBV. Leukophoresed blood was diluted 1:1 with Dulbecco's PBS, layered over 14 mL of Ficoll-Hypaque density gradient in a 50mL centrifuge and then centrifuged for 30 minutes at 600 x g. Banded PBMCs were gently aspirated from the resulting interface and subsequently washed twice with PBS by low speed centrifugation. After the final wash, cells 20 were enumerated by trypan blue exclusion and resuspended at 1×10^7 cells/mL in RPMI 1640 supplemented with 15% Fetal Bovine Serum (FBS), 2mM L-glutamine, and 4 µg/mL PHA-P. The cells were incubated for 48-72 hours at 37°C, then centrifuged and reset in RPMI 1640 with 15% FBS, 2mM L-glutamine, 100 U/mL penicillin, 100µg/mL streptomycin, 10 µg/mL gentamycin, and 20 U/mL recombinant human IL-2. PBMCs were 25 maintained in this medium at a concentration of $1-2 \times 10^6$ cells/mL with bi-weekly medium changes until used in the assay.

30 For the standard PBMC assay, PHA-P stimulated cells from at least two normal donors were pooled, diluted in fresh medium to a final concentration of 1×10^6 cells/mL, and plated in the interior wells of a 96 well round bottom microplate at 50 µL/well (5×10^4 cells/well). Test drug dilutions were prepared at a 2X concentration in microfuge tubes and 100 µL of each concentration was placed in appropriate wells in a standard format. A predetermined dilution of virus stock was placed in each test well (50 µL, final MOI $\cong 0.1$).

Wells with cells and virus alone were used for virus control. Separate plates were prepared identically without virus for drug cytotoxicity studies using an XTT assay system. The PBMC cultures were maintained for seven days following infection, at which time cell-free supernatant samples were collected and assayed for reverse transcriptase activity as described

5

below.

Virus Preparation: Pre-tittered aliquots of HIV-1_{ROJO} and HIV-1_{RF} were removed from the freezer (-80°C) and thawed to room temperature in a biological safety cabinet. The virus was resuspended and diluted into tissue culture medium such that the amount of virus added to each well in a volume of 50 µL will be the amount determined to give complete cell killing at 6 days post-infection. TCID₅₀ calculation by endpoint titration in CEM-SS cells indicated that the multiplicity of infection (MOI) of these assays ranged from 0.005-0.01.

Tetrazolium dye staining of screening plates: After 6 days of incubation (37°C with 5% CO₂), the test plates were analyzed by staining with the tetrazolium dye XTT (2,3-b (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium -5-carboxanilide). XTT-tetrazolium is metabolized by mitochondrial enzymes of metabolically active cells to a soluble formazan product, allowing the rapid quantitative analysis of the inhibition of HIV-induced cell killing by anti-HIV compounds. The XTT solution was prepared daily as a stock of 1 mg/mL in PBS. Phenazine methosulfate (PMS) solution was prepared at 15 mg/mL in PBS and stored in the dark at -20°C. XTT/PMS stock was prepared immediately before use by diluting the PMS 1:100 into PBS and adding 40 µL per ml of XTT solution. Fifty µls of XTT/PMS were added to each well of the plate and the plate was incubated for 4 hours at 37°C. Plates were sealed with adhesive plate sealers and inverted several times to mix the soluble formazan product and the plate was read spectrophotometrically at 450nm with a Molecular Devices Vmax plate reader. Indices such as %CPE Reduction (cytopathic effects), %Cell Viability, IC₂₅, IC₅₀, IC₉₅, TC₂₅, TC₅₀, and TC₉₅ and other indices were calculated. The use of round bottom microtiter plates allowed rapid macroscopic analysis of the activity of a given test compound by the evaluation of pellet size. The results of the macroscopic observations were confirmed and enhanced by further microscopic analysis.

Table 13 provides the toxicity data as percent cell control (%CC) for PBMCs pretreated with N-glycolylneuraminic acid for 2 hours, then infected with HIV_{ROJO}. As indicated in Table 13, no toxicity was observed at concentrations of at least 200mM, i.e., %CC was around 100% at each tested concentration of N-glycolylneuraminic acid. Similar

10

15

20

25

30

results were observed for cells simultaneously exposed to N-glycolylneuraminic acid and HIV_{ROJO}.

TABLE 13
Toxicity of N-glycolylneuraminic Acid Treatment

5

Conc.(mM)	1	0.32	0.1	0.032	0.64	2	6.4	20	64	200
	Sample 1	2.157	2.213	2.282	2.317	2.250	2.255	2.325	2.256	2.014
Sample 2	2.163	2.266	2.717	2.186	2.048	2.595	2.385	2.459	2.065	2.100
Sample 3	1.965	2.230	2.960	2.903	2.866	2.929	2.944	2.631	1.984	2.100
Mean	2.095	2.236	2.653	2.469	2.388	2.593	2.551	2.449	2.021	2.100
%CC	99.8	106.5	126.3	117.6	113.7	123.5	121.5	116.6	96.2	100.0

Reverse Transcriptase Activity Assay: A microtiter based reverse transcriptase (RT) reaction was utilized as described by Buckheit et al., (1991), AIDS Research and Human Retroviruses, 7:295-302. Tritiated thymidine triphosphate (³H-TTP) was suspended in distilled H₂O at 5 Ci/mL. Poly rA and oligo dT were prepared as a stock solution which was kept at -20°C. RT reaction buffer was prepared fresh on a daily basis and contained 125 µL 1M EGTA, 125 µL dH₂O, 110 µL 10% SDS, 50 µL 1M Tris (pH 7.4), 50 µL 1M DTT, and 40 µL 1M MgCl₂. These three solutions were mixed together in a ratio of 2 parts ³H-TTP, 1 part poly rA:oligo dT, and 1 part reaction buffer. Ten microliters of this reaction mixture were placed in a round bottom microtiter plate and 15 µL of virus containing supernatant were added and mixed. The plate was incubated at 37°C in a water bath with a solid support to prevent submersion of the plate and incubated for 60 minutes. After the incubation period, the reaction volume was spotted onto pieces of DE81 paper, washed 5 times for 5 minutes each in a 5% sodium phosphate buffer, 2 times for 1 minute each in distilled water, 2 times for 1 minute each in 70% ethanol, and then dried. Opti-Fluor-O (Packard) was added to each sample and incorporated radioactivity was quantified utilizing a Wallac 1450 MicroBeta Plus liquid scintillation counter. Plates were screened with tetrazolium dye staining as described above.

20

25

Table 14 provides a summary of the RT activity in PBMCs infected with HIV from the ROJO isolate. As shown in Table 14A, RT activity in cells pretreated with about 0.01 to

1 mM of N-glycolylneuraminic acid for about 2 hours was significantly reduced (3.7 to 46.2 % virus control, VC). RT activity in cells pretreated with concentrations of N-glycolylneuraminic acid less than 0.0032 mM was similar to the virus control. The IC₅₀ was approximately 0.010mM and the TC₅₀ was >1mM, resulting in a therapeutic index (TI) of >100. Table 14B provides the RT activity in cells simultaneously exposed to drug and HIV. The IC₅₀ was approximately 0.058mM and the TC₅₀ was >1mM, with a TI of >17.25.

TABLE 14
N-Glycolylneuraminic Acid 2-hour Pretreatment of Infected Human PBMCs

A. Reverse Transcriptase (RT) Activity (cpm)										
Conc. (mM)	1	0.32	0.1	0.032	0.01	0.0032	0.001	0.00032	0.0001	0
Sample 1	72.0	196.0	785.0	156.0	120.0	2381.0	1969.0	2655.0	3776.0	2060.0
Sample 2	68.0	140.0	388.0	564.0	1265.0	3368.0	1129.0	2078.0	3131.0	2060.0
Sample 3	88.0	104.0	204.0	965.0	1469.0	1838.0	2503.0	1313.0	1384.0	2060.0
Mean	76.0	146.7	459.0	561.7	951.3	2529.0	1867.0	2015.3	2763.7	2060.0
% VC	3.7	7.1	22.3	27.3	46.2	122.8	90.6	97.8	134.2	100.0
B. RT Activity (cpm)										
Conc.(mM)	1	0.32	0.1	0.032	0.01	0.0032	0.001	0.00032	0.0001	0
Sample 1	108	132.0	100.0	1814.0	2284.0	3135.0	4950.0	4589.0	2423.0	2992.0
Sample 2	368	108.0	2531.0	2094.0	2280.0	264.0	3912.0	3119.0	2253.0	2992.0
Sample 3	136	68.0	88.0	1694.0	1926.0	5279.0	464.0	677.0	2369.0	2992.0
Mean	204	102.7	906.3	1867.3	2163.3	2892.7	3108.7	2795.0	2348.3	2992.0
%VC	6.8	3.4	30.3	62.4	72.3	96.7	103.9	93.4	78.5	100.0

In the CEM-SS cell-based assay system, N-glycolylneuraminic acid (3.2μM to 1 mM) did not display anti-HIV activity when tested against the laboratory-adapted HIV-1_{RF} and HIV-1_{IIIB} virus strains. Pretreatment with N-glycolylneuraminic acid for two hours did not reveal latent antiviral properties of the test compound. The TC₅₀ of N-glycolylneuraminic acid was greater than 1mM in the CEM-SS cell based assay using HIV-1_{RF} or IIIB, whereas for AZT, the TC₅₀ was greater than 1μM. The IC₅₀ of AZT was calculated to be 0.005 – 0.007μM for HIV-1_{RF} and 0.011-0.017μM for HIV-1_{IIIB}.

N-glycolylneuraminic acid did have anti-HIV activity in the PBMC cell-based assay system. Against the low passage clinical isolate HIV-1_{ROJO}, N-glycolylneuraminic acid was active with and without a 2hr pretreatment of the cells. Activity was strain-specific,

however, as N-glycolylneuraminic acid was inactive against the laboratory strain HIV-1_{IIIB}. The TC₅₀ of N-glycolylneuraminic acid was greater than 1mM in the PBMC cell based assay using HIV-1_{ROJO} or IIIB, whereas for AZT, the TC₅₀ was greater than 4μM. The IC₅₀ of N-glycolylneuraminic acid was approximately 0.058mM without a pretreatment and 0.010mM with a 2hr pretreatment for HIV-1_{ROJO}, whereas the IC₅₀ for AZT was calculated to be 0.008μM without pretreatment and 0.004μM with a 2hr pretreatment. The IC₅₀ for AZT was 0.002μM for HIV-1_{IIIB}.

In this series of experiments, N-glycolylneuraminic acid did not have anti-viral activity against laboratory strains of HIV. It is possible that preservatives such as glycerol contained in these laboratory strains or diluents such as DMSO interfere with the anti-viral activity of N-glycolylneuraminic acid. See, Science, 1996, 274:1393-1395.

Example 6-P-24 Assay for Infected PBMCs Treated with N-Glycolylneuraminic Acid: PBMCs were isolated as described above and incubated with HIV-1 MN (NIH AIDS reagent program, catalog #137) at 37°C for 3 hours in 15mL tubes. Test groups included uninfected PBMCs, infected PBMCs with no N-glycolylneuraminic acid, and infected PBMCs plus N-glycolylneuraminic acid. Concentration of N-glycolylneuraminic acid ranged from about 6.2μg (1:2 dilution) to about 50μg (1:64 dilution). Excess virus was removed by washing the cells with PBS one time then the cells were exposed to N-glycolylneuraminic acid. P24 output was measured using the DuPont P24 assay kit (optical density (OD) in Table 15). Syncytia formation was examined as well as cytopathic effects (CPE). Mean p24 output was $9.68 \times 10^6 \pm 3.24 \times 10^6$ pg HIV-1P24/ml in unreacted samples (no N-glycolylneuraminic acid) and 624 ± 326 pg HIV-1P24/ml in samples treated with N-glycolylneuraminic acid (corrected for dilution factor). Sample #7 (p24 123×10^6 pg HIV-1P24/ml) was excluded from the mean P24 output calculation due to a sampling error. In unreacted samples, cell viability was 19%, whereas in samples treated with N-glycolylneuraminic acid, cell viability was 25%. As indicated in Table 15, syncytia formation and HIV-induced cytopathic effects were prevented in infected cells by treatment with N-glycolylneuraminic acid.

5

10

20

25

30

TABLE 15
P24 output in Infected PBMCs

Sample #	O.D.	P-24*	Syncytia	CPE
1-4 Uninfected-PBMCs	0.099	70	negative	negative
	0.117	89	negative	negative
	0.055	135	negative	negative
	0.012	90	negative	negative
5-10 Infected-PBMCs-no Neu5Gc	0.469	14.7 x10 ⁶	positive	4+
	0.417	10.9 x10 ⁶	positive	4+
	0.235	6.66 x10 ⁶	positive	4+
	0.389	8.82 x10 ⁶	positive	4+
	0.249	7.3 x10 ⁶	positive	4+
11-16 Infected-PBMCs-Neu5Gc 1:2	0.017	320	negative	negative
1:4	0.043	922	negative	negative
1:8	0.057	871	negative	negative
1:16	0.061	824	negative	negative
1:32	0.012	265	negative	negative
1:64	0.041	865	negative	negative

*P-24 as picograms HIV-1 p24 per mL

Example 7-Assessment of Cell Proliferation in Cells Treated with N-glycolylneuraminic acid:

N-glycolylneuraminic acid: On day 0, cell lines listed in Table 16 were plated into microtiter plates at 850-2000 cells/ well in 100 μ L of media. On day 1, N-glycolylneuraminic acid was diluted 2X in medium and from 0 to 200 μ M of N-glycolylneuraminic acid or 1000 μ M of N-glycolylneuraminic acid were added. The stock solution at 50/250 mM in DMSO then was diluted 1/500 in media, $V_f = 200\mu$ L/well. The cells were incubated for 3 days at 37°C and 5% CO₂. On day 4, ³[H]-thymidine, diluted 1/100 in media, was added at 25 μ L/well/200 μ L of medium, resulting in a final concentration of 0.5 μ Ci per well. On day 5, cells were harvested (18 hours after the addition of the ³[H]-thymidine) onto a glass fiber, and CPM/ well were determined. The results are listed in Table 16.

TABLE 16
Treated Cell Lines

Cell Line	Description	Plating cpm (day 0)	% Confluence (day 5)
<i>Molt-4</i>	Peripheral blood, acute lymphoblastic leukemia, human.	2000	50
<i>DU-145</i>	Prostate carcinoma, metastasis to brain, human	1200	100
<i>HSF</i>	Human foreskin fibroblast, diploid, normal.	1000	100
<i>HT1080</i>	Fibrosarcoma, epithelial-like, human.	850	100
<i>HepG2</i>	Hepatocellular carcinoma, human.	2000	50

Example 8—Comparison of Inhibition of LUKOR, N-Glycolylneuraminic Acid, and N-Acetylneuraminic Acid: The RT assay described in Example 5 was used to compare the inhibitory activity of LUKOR, N-glycolylneuraminic acid, and N-acetylneuraminic acid. PBMCs were treated with dilutions of LUKOR of 1:4, 1:20, 1:100, 1:500, or 1:2500, or concentrations of N-glycolylneuraminic acid or N-acetylneuraminic acid of 0.4, 1.2, 3.6, 11, or 33 μ g/ml. No carbohydrates were added to the control sample. RT activity was determined at 3, 6, 9, 13, 17, and 20 days post-infection (PI) with X4 strain LAI/IIIB.

Results are shown in Table 17. RT activity was decreased in cells treated with LUKOR, with the 1:4 and 1:20 dilutions of LUKOR most effective. In N-glycolylneuraminic acid treated samples, RT activity was decreased, especially with the middle concentrations (1.2 and 3.6 μ g/ml). In contrast, decreased RT activity was observed only with high concentrations of N-acetylneuraminic acid. Figures 3A-3C are graphs that illustrate the inhibitory properties.

TABLE 17
RT Activity in Infected Cells Treated with Carbohydrates

Days PI	Control	LUKOR				
		1:4	1:20	1:100	1:500	1:2500
3	56	34	81	66	21	51
6	255	117	116	1180	81	73
9	1879	783	989	5615	891	765
13	3046	556	409	4421	1874	1211
17	3312	2326	795	1453	2580	2131
20	1723	1940	143	3250	719	1808
Days PI	Control	N-glycolylneuraminic acid µg/ml				
		33	11	3.6	1.2	0.4
3	56	32	40	45	35	53
6	255	75	75	44	39	113
9	1879	567	956	139	280	1342
13	3046	1103	2544	428	100	1371
17	3312	2356	3261	1262	449	1509
20	1723	2917	1411	616	385	1250
Days PI	Control	N-acetylneuraminic acid µg/ml				
		33	11	3.6	1.2	0.4
3	56	36	43	83	34	89
6	255	53	75	508	83	129
9	1879	165	799	1902	982	878
13	3046	442	2047	1892	2192	2703
17	3312	1273	2990	1260	1246	1615
20	1723	1526	1171	836	762	812

Example 9 – Inhibition of Tumor Necrosis Factor (TNF) with N-

Glycolylneuraminic Acid: TNF α production was examined in latently infected promonocytic U1 cells that were incubated in the presence of N-glycolylneuraminic acid (0.1 to 316 μ M). TNF α production was determined by an enzyme linked immunosorbent assay (ELISA) in a competitive format, using a commercially available anti-TNF α antibody. Inhibition of TNF α production is reported as percent of saline control in Table 18 and was dose dependent. Based on the inhibition of TNF α production, N-glycolylneuraminic acid also may be useful for treatment of immune-mediated diseases such as cancer, and in particular, HIV-related cancers.

10

TABLE 18
Inhibition of TNF α Production in U1 Cells

Conc. of N-Glycolylneuraminic Acid (μM)	Inhibition of TNFα Production % of Control
0.1	0
0.3	0
10	9.8
30	22.6
100	96

15

Example 10 – Inhibition of gp120 binding: The effect of N-glycolylneuraminic acid on preventing binding of HIV_{MN} to CEM-SS cells was assessed. Concentrations of N-glycolylneuraminic acid ranged from 10-200 μ m/ml. Saline was used as the control. Results are reported in Table 19 as percent inhibition of gp120 binding. Inhibition of binding was dose-dependent.

20

TABLE 19
Inhibition of gp120 binding

Conc. of N-Glycolylneuraminic Acid (μm/ml)	Inhibition of gp120 Binding (% of control)
10	3.4
20	9.8
40	34.1
80	57.6
200	86.8

25

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.

5 Other aspects, advantages, and modifications are within the scope of the following claims.

What is claimed is:

1. A method for preventing or treating a viral infection in a subject, said method comprising administering N-glycolylneuraminic acid or a derivative thereof to said subject in an amount effective to prevent or treat said viral infection.
2. The method of claim 1, wherein said viral infection is from an enveloped retrovirus.
3. The method of claim 1, wherein said viral infection is from HIV.
4. The method of claim 1, wherein said viral infection is from hepatitis virus.
5. The method of claim 1, wherein said viral infection is from a herpes virus.
6. The method of claim 1, wherein said N-glycolylneuraminic acid or said derivative thereof is administered intravenously.
7. The method of claim 1, wherein said N-glycolylneuraminic acid or said derivative thereof is administered subcutaneously.
8. The method of claim 1, wherein said N-glycolylneuraminic acid or said derivative thereof is administered orally.
9. The method of claim 1, wherein said N-glycolylneuraminic acid or said derivative thereof is administered by inhalation.
10. The method of claim 1, wherein said N-glycolylneuraminic acid or said derivative thereof is administered transdermally.
11. The method of claim 1, said method further comprising monitoring said subject for the presence of said viral infection.
12. The method of claim 1, wherein said amount of N-glycolylneuraminic acid or said derivative thereof is about 1 mg to about 1000 mg per administration.
13. The method of claim 12, wherein said amount of N-glycolylneuraminic acid or said derivative thereof is about 10 mg to about 100 mg per administration.
14. The method of claim 13, wherein said amount of N-glycolylneuraminic acid or said derivative thereof is about 30 mg to about 80 mg per administration.
15. The method of claim 1, wherein said amount of N-glycolylneuraminic acid or said derivative thereof is administered daily.
16. The method of claim 1, wherein N-glycolylneuraminic acid is administered.

17. The method of claim 1, wherein said derivative is phosphorylated N-glycolylneuraminic acid.
18. The method of claim 1, wherein said derivative is sulfated N-glycolylneuraminic acid.
19. The method of claim 16, wherein said N-glycolylneuraminic acid is synthetic.
20. The method of claim 16, wherein said N-glycolylneuraminic acid is extracted from a biological sample.
21. A method for treating an immune mediated disease in a patient, said method comprising administering N-glycolylneuraminic acid or a derivative thereof to said patient in an amount effective to treat said immune mediated disease in said patient.
22. The method of claim 21, wherein said immune mediated disease is cancer.
23. A method for preventing or treating a pathogenic infection in a patient, said method comprising administering N-glycolylneuraminic acid or a derivative thereof to said patient in an amount effective to prevent or treat said pathogenic infection.
24. The method of claim 23, wherein said pathogenic infection is a bacterial infection.
25. The method of claim 23, wherein said pathogenic infection is a parasite.
26. The method of claim 23, wherein said pathogenic infection is influenza.
27. The method of claim 23, wherein said pathogenic infection is malaria.
28. A method for treating a blood product intended for transfusion into a subject, said method comprising adding N-glycolylneuraminic acid or a derivative thereof to said blood product in an amount effective to reduce or eliminate the risk of infection of said subject with a pathogen associated with transfusion of said blood product.
29. A method for treating a viral infection in a subject, said method comprising administering a first anti-viral agent and a second anti-viral agent to said subject in amounts effective to treat said viral infection, wherein said first anti-viral agent is N-glycolylneuraminic acid or a derivative thereof.
30. The method of claim 29, wherein said first and second anti-viral agents are conjugated to each other.
31. The method of claim 29, wherein said second anti-viral agent is a reverse transcriptase inhibitor or a protease inhibitor.

ABSTRACT OF THE INVENTION

Methods for preventing or treating a viral infection in a subject are described that include administering N-glycolylneuraminic acid or a derivative thereof to the subject.

60003000.doc

Reverse Transcriptase Assay for HIV Infected CEM-TART Cell Culture Supernatant




FIGURE 1






FIGURE 2

A. LUKOR Effect on RT Activity



B. N-Glycolylneuraminic Acid Effect On RT-Activity



C. N-acetylneuraminic Acid Effect on RT Activity




FIGURE 3

12/29/99 13:06 FAX 202 835 75867

MTHM DC

002

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**DECLARATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

TREATMENT AND PREVENTION OF HIV AND OTHER VIRAL INFECTIONS

the specification of which (check one)

is attached hereto.

was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the column, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Day/Month/Year Filed	Priority Not Claimed

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
60/114,540	December 29, 1998

Mark L. Lamm
Dec. 29, 1999

12/29/99 14:13 FAX 202 835 75867

MTHM DC

003

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application designating the United States, listed below:

Application Serial No.	Filing Date	Status
09/015,830	January 29, 1998	Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorney(s) with full power of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Christopher E. Chalsen, Reg. No. 30,936; W. Jackson Matney, Jr., Reg. No. 59,292; John M. Griesm, Jr., Reg. No. 40,005; Michael H. Jacobs, Reg. No. 41,870; James Klaiber, Reg. No. 41,902; Mark S. Ellinger, Ph.D., Reg. No. 34,812 and Monica McCormick Graham, Ph.D., Reg. No. 42,600

Send correspondence, and direct telephone calls to:

W. Jackson Matney, Jr.
Milbank, Tweed, Hadley & McCloy LLP
International Square Building
1825 Eye Street, N.W.
Washington, D.C. 20006
Phone: (202) 835-7500
Fax: (202) 835-7586

Full name of sole or first inventor:

Yash Sharma

Residence/Post Office Address:

8210 Labbe Lane
Vienna, VA 22182

Citizenship:

United States

Mark S. Ellinger
Inventor's Signature

Date

Dec 29, 1999